Cardiff Oncology, Inc.
CRDF
$1.53
$0.032.00%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -10.71% | -13.30% | -27.29% | -17.89% | -3.61% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -10.71% | -13.30% | -27.29% | -17.89% | -3.61% |
| Cost of Revenue | -19.59% | -4.14% | 14.50% | 24.40% | 23.60% |
| Gross Profit | 19.73% | 3.96% | -15.34% | -25.27% | -24.14% |
| SG&A Expenses | 22.22% | 13.96% | 16.76% | 12.16% | 2.11% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -8.99% | 0.44% | 15.09% | 21.16% | 17.34% |
| Operating Income | 8.97% | -0.64% | -15.72% | -21.74% | -17.63% |
| Income Before Tax | 8.38% | -0.92% | -17.31% | -24.87% | -21.44% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 8.38% | -0.92% | -17.31% | -24.87% | -21.44% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 8.38% | -0.92% | -17.31% | -24.87% | -21.44% |
| EBIT | 8.97% | -0.64% | -15.72% | -21.74% | -17.63% |
| EBITDA | 8.96% | -0.72% | -15.94% | -22.02% | -17.82% |
| EPS Basic | 28.82% | 28.24% | 15.98% | 3.48% | -3.84% |
| Normalized Basic EPS | 28.82% | 28.23% | 15.96% | 3.45% | -3.86% |
| EPS Diluted | 28.82% | 28.24% | 15.98% | 3.48% | -3.84% |
| Normalized Diluted EPS | 28.82% | 28.23% | 15.96% | 3.45% | -3.86% |
| Average Basic Shares Outstanding | 26.72% | 40.28% | 40.38% | 30.90% | 18.87% |
| Average Diluted Shares Outstanding | 26.72% | 40.28% | 40.38% | 30.90% | 18.87% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |